Thromb Haemost 1995; 74(06): 1528-1532
DOI: 10.1055/s-0038-1649977
Original Articles
Fibrinolysis
Schattauer GmbH Stuttgart

Inhibitors of Plasminogen Activator in Neutrophils and Mononuclear Cells from Septic Patients

Montaser A Haj
The Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, UK
,
Linda A Robbie
The Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, UK
,
Gillian D Adey
1   The Department of Anaesthetics, Aberdeen Royal Hospitals NHS Trust, Aberdeen, UK
,
Bruce Bennett
The Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, UK
› Author Affiliations
Further Information

Publication History

Received 07 July 1995

Accepted after revision 12 September 1995

Publication Date:
10 July 2018 (online)

Summary

Leucocytes, both polymorphs and mononuclear cells, play a variety of roles in the evolution of human response to sepsis, both local and generalised. In this study, inhibitors of plasminogen activator were measured in leucocytes from normal and septic patients. Plasminogen activator inhibitor-1 (PAI-1) was identified in polymorphs from normal individuals and levels rose significantly in polymorphs from septic patients: neutrophils from normal subjects did not contain PAI-2 but this protein was detectable in significant quantities in polymorph preparations from septic patients. In contrast, mononuclear cells from normal and septic patients contained no detectable quantities of PAI-1. Significant amounts of PAI-2 were present in normal mononuclear cells, and the levels rose significantly in monocytes from septic patients. PAI-2 is thus here identified in human subjects, distinct from those with pregnancy or malignancy, as playing a role in a pathological process. The increased levels of both inhibitors produced by leucocytes may clearly contribute directly to the persistence of fibrin, a characteristic feature of the response to infection, local or general; they may thus participate in successful localisation of infections (abscess formation etc.) and in the evolution of the major systemic complications of disseminated sepsis characterised by microvascular occlusion by fibrin such as renal failure, shock lung or digital ischaemia.

 
  • References

  • 1 Niemetz J, Fani K. Role of leukocytes in blood coagulation and generalized Schwartzman reaction. Nature New Biol 1971; 232-47
  • 2 Stetson CA Jr, Good RA. Studies on the mechanism of generalized Schwartzman reaction phenomenon. Evidence for the participation of polymorphonuclear leukocytes in the phenomenon J Exp Med 1951; 93: 49-63
  • 3 Forman EN, Abildgaard CF, Bolger JF, Johnson CA, Schulman I. Generalized Schwartzman reaction: role of granulocyte in intravascular coagulation and renal cortical necrosis. Br J Haematol 1969; 16: 507-515
  • 4 Edwards RL, Rickies FR. Macrophage procoagulant. In: Progress in Haemostasis and Thrombosis. Spaet TH. (ed) Vol 7 Orlando, FL: Grune & Stratton; 1985. p 183
  • 5 Naworth PP, Stern DM. Modulation of endothelial cells haemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
  • 6 Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG. Neutrophils- mediated endothelial injury in vitro. Mechanisms of cell detachment. J Clin Invest 1981; 68: 1394-1403
  • 7 Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelets agonist released by neutrophils. Biochem J 1988; 251: 293-297
  • 8 Evangelista V, Rajtar G, de Gaetano G, White JG, Cerletti C. Platelets activation by fMLP-stimulated polymorphonuclear leukocytes: the activity of cathepsin G is not prevented by antiproteases. Blood 1991; 77: 2379
  • 9 Plow EF, Edgington TS. An alternative pathway for fibrinolysis I.The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 1975; 36: 30-38
  • 10 Bilezikian SB, Nossel HL. Unique pattern of fibrinogen cleavage by human leukocytes proteases. Blood 1977; 50: 21-28
  • 11 Egbring R, Schmidt W, Fuchs G, Havemenn K. Demonstration of granulocytic proteases in plasma of patients with acute leukaemia and septicaemia with coagulation defects. Blood 1977; 49: 219-231
  • 12 Romson JL, Hook BG, Kunkel SL. Reduction of the extent of ischaemic myocardial injury by neutrophil depletion in the dog. Circulation 1983; 67: 1016
  • 13 Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: Fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71: 511-517
  • 14 Janeoff A, Scherer J. Mediators of inflammation in leukocyte lysosomes. J Exp Med 1968; 128: 1137-1151
  • 15 Gilboa N, Neumann PH, Gutman JM, Del Vecchio PJ, Gudewicz PM. Evidence for regulation of endothelial plasminogen-activating system by polymorphonuclear leukocytes elastase. Thromb Res 1989; 54: 467-475
  • 16 Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of haemostasis in septic shock: role of neutrophil elastase and thrombin effects of antithrombin III and plasma substitution. Eur J Haematol 1989; 43: 22-28
  • 17 Haj MA, Neilly IJ, Robbie LA, Adey G, Bennett B. Influence of white blood cells on the fibrinolytic response to sepsis: studies on septic patients with or without severe leucopenia. Br J Haematol 1995; 90: 541-547
  • 18 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor in plasma and platelets. Br J Haematol 1988; 70: 327-333
  • 19 Ritchie H, Jamieson A, Booth NA. Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. (Submitted for publication 1995)
  • 20 Booth NA, Anderson JA, Bennett B. The plasma inhibitors of plasminogen activator, studied by a zymographic technique. Thromb Res 1985; b 38: 261-267
  • 21 Reith A, Bennett B, Booth NA. Plasminogen activator inhibitor (PAI-2) in pregnancy plasma and ovarian cyst; studies by zymography after nondenaturing gel electrophoresis. Fibrinolysis 1989; 3: 159-163
  • 22 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-I) in tissues. J Clin Pathol 1991; 44: 139-143
  • 23 Niemetz J. Coagulation activity of leucocytes. J Clin Invest 1972; 51: 307-313
  • 24 Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 1984; 10: 23-28
  • 25 Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
  • 26 Kruithof EK O, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59: 7-12
  • 27 Wun T-C, Reich E. An inhibitor of plasminogen activation from human placenta: Purification and characterization. J Biol Chem 1987; (8) 262: 3646-3653
  • 28 Schwartz BS, Monroe MC, Levin EG. Increase release of plasminogen activator inhibitor type-2 accompanies the human mononuclear cells tissue factor response to lipopolysaccharide. Blood 1988; 71 (03) 734-741
  • 29 Castellote JC, Grau E, Linde MA, Pujol-Moix N, Rutllant ML. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost 1990; 63: 67-71
  • 30 Robbie LA, Bennett B, Brown PA J, Croll AM, Booth NA. Activators and inhibitors of the fibrinolytic system in human thrombi. Thromb Haemost. 1996 in press